Emphycorp, Inc.
Emphycorp’s
investigational new drug, N115, is currently starting
Phase II studies. N115 showed good bronchodilation
activity in some of the end-points in the Phase I
studies. This was unexpected; N115 was (and is)
expected to be a strong anti-inflammatory agent that
will show strong efficacy in multi-dose studies due to
control of any inflammation. The dosing is by
inhalation.
N115 has been
granted Orphan Drug Status by the FDA for both Cystic
Fibrosis and Interstitial Lung Disease
The use of this
compound for this application is heavily patented.
Clinical studies
currently underway include:
-
6 week, double
blind, placebo controlled, study of COPD patients to
investigate the longer-term anti-inflammatory
effects
-
A
single dose study to measure blood oxygen saturation
after dosing. There is good scientific evidence
that N115 could show increased oxygen saturation
after inhalation
-
A pilot
investigation of the use of N115 to treat Cystic
Fibosis
-
A single-dose,
double-blind, placebo-controlled study to confirm
N115’s bronchodilation effects.
Further
information is available at
www.emphycorp.com
Licensing
enquiries should be addressed to JASRA
